Latest news
Redx resumes RXC004 trial after MHRA approval
Redx has received
approval from the UK’s Medicines and Healthcare products Regulatory Agency
(MHRA) to re-commence the phase 1/2a trial for RXC004, an oral...
Record M&A activity for life sciences sector
Last year, mergers and acquisitions activity in the life sciences sector totalled $198 billion as companies focused on building therapeutic scale and...
NICE recommends Eli Lily’s Verzenios for metastatic breast cancer
Eli Lily has secured marketing
authorisation from NICE for Verzenios (abemaciclib) in combination with an
aromatase inhibitor for treating metastatic breast cancer.
